Research

Our researchers in the Fairlie Group at the University of Queensland, Brisbane, Australia, study CHEMISTRY, BIOCHEMISTRY and PHARMACOLOGY  to better understand the detailed processes of life, ageing, disease and death. The Fairlie group works at the interface of chemistry, biology and disease. We apply our skills in MEDICINAL CHEMISTRY and organic chemistry, biochemistry and pharmacology to develop new treatments for human inflammatory diseases, cancers, metabolic diseases (type 2 diabetes, obesity, cardiovascular), viral infections, and Alzheimer's disease. We also execute basic research to understand fundamental principles and processes in chemistry (medicinal, organic, biological, computational, inorganic), biochemistry (proteins, enzymes), pharmacology (cells, rodents, human tissues) and IMMUNOLOGY (neutrophils, macrophages, mast cells, dendritic cells, complement, T cells, rodents).

​

The Fairlie Group's focus on diseases involves basic, strategic and applied research in biochemistry, pharmacology and virology directed at: (1) understanding how the immune system resolves infection (by parasites, viruses, bacteria) and tissue injury; (2) how prolonged inflammatory responses can cause debilitating chronic inflammatory diseases, including onset of cancers, metabolic diseases (obesity, type 2 diabetes, atherosclerosis, cardiovascular diseases), chronic inflammatory pain, and neurodegenerative diseases (e.g. Alzheimer's disease); and (3) how our novel compounds can act on human proteins, human and rodent cells and tissues, and rat or mouse models of human diseases. See links for our publications in all of these disease areas and allied chemical, biochemical and pharmacological research.